IMIDIA

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2010
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • Disease focus:
    Diabetes
  • Location: Europe

Abstract

A complete or relative decrease in insulin secretion by pancreatic beta cells underlies the development of, respectively, Type 1 and Type 2 diabetes. Largely because of limited knowledge of beta-cell biology in health and disease, symptomatic therapeutic options for treatment of diabetes are available, but none cure or prevent this pandemic disease. Although considerable knowledge has been gained on the function of beta cells from animal models, knowledge of human beta-cell function, survival, and the pathophysiological mechanisms that lead to their demise remains limited. The “Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in Diabetes” (IMIDIA) project brings together academic teams, pharmaceutical companies, and a small to medium-sized enterprise, which provides a unique blend of expertise and forms a strong basis for a successful enterprise to ultimately improve industrial competitiveness and public health in Europe. The expected duration of the project is 60 months.

Mission

IMIDIA aims at delivering the following:

Consortium History

Jan. 2, 2010: Project launched
June 14-15, 2010: IMI Stakeholder Forum took place
2013: IMIDIA organized a satellite symposium of the consortia of the IMI Diabetes Platform at the European Association for the Study of Diabetes meeting in Barcelona

Structure & Governance

Coordination Team Members:
Servier: A. Ktorza

Project Coordinator
W. Kramer
Sanofi-Aventis GmbH
Frankfurt, Germany

Managing Entity of IMI Beneficiaries
Bernard Thorens
Department of Physiology & Center for
Integrative Genomics
Université de Lausanne
Lausanne, Switzerland

Financing

This project is funded by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), resources of which consist of financial contribution from the European Union Seventh Framework Programme and EFPIA companies’ in kind contribution. Large pharmaceutical companies participating in IMI projects do not receive IMI funding.

Contributions consist of €7.0 million from IMI, €15.1 million in kind from EFPIA, and €3.8 million from other sources, for a total cost of €25.9 million. 

Intellectual Property

The IMI intellectual property (IP) policy governs the IP regime of all projects funded by the IMI Joint Undertaking. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by emailing IMI-IP-Helpdesk@imi.europa.eu. The IMI IP policy can be accessed at  http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf

Data Sharing

According to IMI’s IP policy, participants undertake to disseminate the data as soon as reasonably practicable but not later than one year after the termination or expiry of the project. The project agreement shall include a description of the material that must be disseminated in accordance with the IP policy and referenced in the grant agreement. If participants do not disseminate within such time periods without good reason, then the Executive Office has the right to disseminate such results in a manner consistent with the grant agreement.

Impact/Accomplishment

The list of publications by IMIDIA members can be found at http://www.imidia.org/publications/imidia-members.php

The list of IMIDIA-derived publications can be found at http://www.imidia.org/publications/imidia-derived.php

Points of Contact

contact@imidia.org

Sanofi-Aventis GmbH
Frankfurt, Germany

Bernard Thorens
Department of Physiology & Center for
Integrative Genomics
Université de Lausanne
Lausanne, Switzerland

Sponsors & Partners

AstraZeneca AB

Boehringer Ingelheim International GmbH

Centre National de la Recherche Scientifique (CNRS)

Commissariat à l’Energie Atomique

Eli Lilly Ltd., Basingstoke

Endocells SARL

F. Hoffmann-La Roche AG

Imperial College of Science, Technology and Medicine

Institut De Recherches Servier

Institut National de la Santé et de la Recherche Medicale (INSERM)

Institut Suisse de Bioinformatique

Medizinische Hochschule Hannover

Novartis Pharma AG

Novo Nordisk A/S

Sanofi-Aventis GmbH

Technische Universität Dresden

Universita di Pisa

Université de Geneve

Université de Lausanne

Université Paris Diderot - Paris 7

Vrije Universiteit Brussel


Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.